Further research shows that cinobufotalin can inhibit the level of β-catenin, increase the expression level of E-cadherin, and decrease the level of N-cadherin, thereby inhibiting the EMT of HCC. This evidence concerns the gene CDH2 and hepatocellular carcinoma.